Hosted on MSN13d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Morningstar14d
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...
Pharmaceutical Technology on MSN1d
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection
Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
PMLive11d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Crain's Chicago Business13d
Europe poised to OK another use for AbbVie's Rinvoq
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
PharmaTimes1d
Rxulti approved in the European Union for adolescent schizophrenia
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
PharmaTimes2d
Orphelia Pharma explores other pathways for paediatric cancer treatment
Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...
Morningstar14d
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP ...
Mena FN11d
The Committee For Medicinal Products For Human Use (CHMP) Reaffirms Positive Opinion For Lecanemab In Early Alzheimer's Disease
(MENAFN- JCN NewsWire) The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Mar 3, 2025 ...
Yahoo Finance14d
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...